John A. Herrmann, II net worth and biography

John Herrmann, II Biography and Net Worth

President, CEO & Director of Novavax

Mr. Herrmann joined Novavax in 2010 and is responsible for managing all of its legal affairs, including its patent portfolio, transactional and contractual matters, and public securities filings, and oversight of corporate and business development activities, along with attending to all the duties of corporate secretary. Mr. Herrmann also works with the senior management team at Novavax to define and develop corporate policies and procedures. Prior to joining Novavax, Mr. Herrmann was general counsel at Ore Pharmaceuticals and deputy general counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann previously worked as senior counsel for Celera Genomics and as senior corporate counsel at Baxter Healthcare in its renal division. Mr. Herrmann received a bachelor of arts degree in political science and history from Brown University and a juris doctorate from the University of Illinois.

What is John A. Herrmann, II's net worth?: The estimated net worth of John A. Herrmann, II is at least $9,051.38 as of July 26th, 2021. Mr. Herrmann, II owns 1,123 shares of Novavax stock worth more than $9,051 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Herrmann, II may own. Learn More about John A. Herrmann, II's net worth.
How do I contact John A. Herrmann, II?: The corporate mailing address for Mr. Herrmann, II and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]. Learn More on John A. Herrmann, II's contact information.
Has John A. Herrmann, II been buying or selling shares of Novavax?: John A. Herrmann, II has not been actively trading shares of Novavax within the last three months. Most recently, John A. Herrmann III sold 5,000 shares of the business's stock in a transaction on Monday, January 3rd. The shares were sold at an average price of $140.91, for a transaction totalling $704,550.00. Learn More on John A. Herrmann, II's trading history.
Who are Novavax's active insiders?: Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (President, CEO & Director), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.
Are insiders buying or selling shares of Novavax?: During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 62,312 shares worth more than $866,211.80. The most recent insider tranaction occured on June, 21st when Director James F Young sold 7,500 shares worth more than $105,675.00. Insiders at Novavax own 1.0% of the company. Learn More about insider trades at Novavax.
Information on this page was last updated on 6/21/2024.

John A. Herrmann, II Insider Trading History at Novavax

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/3/2022	Sell	5,000	$140.91	$704,550.00
12/20/2021	Sell	5,000	$230.00	$1,150,000.00
12/1/2021	Sell	5,000	$196.19	$980,950.00
11/29/2021	Sell	5,000	$228.72	$1,143,600.00
11/3/2021	Sell	5,000	$200.00	$1,000,000.00
11/1/2021	Sell	5,000	$163.08	$815,400.00
10/1/2021	Sell	5,000	$174.89	$874,450.00
9/1/2021	Sell	5,000	$247.97	$1,239,850.00
7/26/2021	Sell	2,896	$197.74	$572,655.04	1,123
5/28/2021	Sell	2,895	$149.14	$431,760.30	691
4/30/2021	Sell	2,895	$239.83	$694,307.85	691
3/26/2021	Sell	2,894	$186.80	$540,599.20	691
2/26/2021	Sell	2,895	$225.48	$652,764.60	691
9/28/2020	Sell	24,750	$110.30	$2,729,925.00	43,054
8/18/2020	Sell	46,242	$144.33	$6,674,107.86	1,275
9/17/2019	Sell	3,643	$7.07	$25,756.01
1/31/2017	Buy	4,960	$1.12	$5,555.20
12/16/2015	Sell	27,945	$8.64	$241,444.80	40

John A. Herrmann, II Buying and Selling Activity at Novavax

Novavax Company Overview

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $8.06

$7.76

$8.16

50 Day Range

MA: $11.07

$7.22

$14.68

2 Week Range

Now: $8.06

$3.53

$23.86

Volume

3,465,617 shs

Average Volume

5,856,114 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>